GeneDx Holdings Corp. (WGS) Financial Statements
Industry: Health Services (Services)
In fiscal 2025, GeneDx reported revenue of $427.5M, up 40.0% from $305.4M the year before. Net income was -$21.0M (a -4.9% net margin), or -$0.73 per diluted share. Gross margin was 69.7% and operating margin was -3.1%. Operating activities generated $33.3M of cash, leaving $14.3M of free cash flow. At fiscal year end, GeneDx held $523.7M in total assets against $215.5M in total liabilities, including $105.0M of cash and equivalents.
Open the full interactive GeneDx financials → Quarterly statements, key ratios, valuation history and price charts.
GeneDx Key Stats
| Share Price | $64.96 |
|---|---|
| Market Cap | $1.93B |
| Revenue YoY Growth | +40.0% |
| 52-Week Range | $34.51 – $167.51 |
| Shares Outstanding | 29.7 million (basic, 2026 Q2) |
GeneDx Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $212.2M | $234.7M | $202.6M | $305.4M | $427.5M |
| Cost of Goods Sold | $0 | $228.8M | $261.4M | $112.6M | $111.1M | $129.4M |
| Gross Profit | $0 | -$16.6M | -$26.8M | $90.0M | $194.4M | $298.2M |
| Operating Income | — | -$446.1M | -$667.7M | -$180.6M | -$23.2M | -$13.1M |
| Pre-Tax Income | $0 | -$245.4M | -$598.0M | -$176.7M | -$52.6M | -$21.1M |
| Income Tax | — | $0 | -$49.1M | -$926,000 | -$343,000 | -$116,000 |
| Net Income | $0 | -$245.4M | -$549.0M | -$175.8M | -$52.3M | -$21.0M |
| Diluted EPS | — | -$74.91 | -$53.79 | -$7.23 | -$1.94 | -$0.73 |
GeneDx Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $116.7M | $121.0M | $102.3M | $114.4M |
| Net Income | -$7.6M | -$17.7M | -$63.3M | -$17.7M |
| Diluted EPS | -$0.27 | -$0.62 | -$2.16 | -$0.60 |
GeneDx Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.1M | $400.6M | $123.9M | $99.7M | $85.2M | $105.0M |
| Current Assets | $1.4M | $483.5M | $212.6M | $182.3M | $198.0M | $268.3M |
| Total Assets | $444.1M | $554.1M | $490.9M | $418.8M | $419.4M | $523.7M |
| Current Liabilities | $97,120 | $101.3M | $144.3M | $58.8M | $54.8M | $108.9M |
| Total Long-Term Debt | — | $11.0M | $11.0M | $53.2M | $53.1M | $52.7M |
| Total Liabilities | $85.9M | $166.0M | $237.2M | $190.7M | $174.1M | $215.5M |
| Shareholders' Equity | $5.0M | $388.1M | $253.7M | $228.0M | $245.2M | $308.2M |
GeneDx Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$386,106 | -$190.4M | -$319.2M | -$180.1M | -$28.5M | $33.3M |
| Cash From Investing | -$442.8M | -$20.8M | -$141.3M | -$43.7M | -$30.1M | -$61.5M |
| Cash From Financing | $444.2M | $493.7M | $197.3M | $186.2M | $44.2M | $48.0M |
| Free Cash Flow | — | -$199.8M | -$326.3M | -$185.4M | -$34.0M | $14.3M |
Figures from GeneDx's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full GeneDx financials page for every line item.
GeneDx Company Profile
| Ticker | WGS |
|---|---|
| Exchange | Nasdaq |
| Industry | Health Services (Services) |
| Headquarters | Stamford, Connecticut |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Large accelerated filer |
| SEC CIK | 0001818331 |
Frequently Asked Questions
What was GeneDx's revenue in fiscal 2025?
GeneDx (WGS) reported revenue of $427.5M for fiscal 2025.
What is GeneDx's annual revenue history?
GeneDx's annual revenue by fiscal year: 2020: $0; 2021: $212.2M; 2022: $234.7M; 2023: $202.6M; 2024: $305.4M; 2025: $427.5M.
What was GeneDx's net income in fiscal 2025?
GeneDx reported net income of -$21.0M for fiscal 2025.
What was GeneDx's earnings per share (EPS) in fiscal 2025?
GeneDx's diluted EPS was -$0.73 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did GeneDx generate in fiscal 2025?
GeneDx generated $14.3M of free cash flow in fiscal 2025.
What was GeneDx's revenue last quarter?
In its most recent reported quarter (2026 Q2), GeneDx reported revenue of $114.4M.
How much debt does GeneDx have?
GeneDx reported $52.7M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of GeneDx are outstanding?
GeneDx reported a weighted average of 29.7 million basic shares outstanding in 2026 Q2.
What is GeneDx's market cap?
Based on its latest closing price, GeneDx (WGS) has a market capitalization of about $1.93B.
When does GeneDx's fiscal year end?
GeneDx's fiscal year end, as registered with the SEC, is December 31.
Where is GeneDx headquartered?
GeneDx lists its business address in Stamford, Connecticut in its SEC filings.